BIONTECH SE
Company Snapshot
Founded: 2008
Entity Type: Public
Employees: 6,772
Region: U.S.
Revenue: $2,977.3 Millions
Revenue Year: 2024
Headquarter: Mainz, Germany
Key Geographics: U.S., Germany, Rest of the World
Corporate Address: An der Goldgrube 12, 55131 Mainz, Germany Tel. +49-6131-9084-0 www.biontech.com
Company Overview
BioNTech SE is a biotechnology firm based in Mainz, Germany, focusing on developing and commercializing immunotherapies to treat cancer and infectious diseases. It operates through two segments: immuno-oncology and infectious disease vaccines. The company is focused on harnessing mRNA technology, cell therapies, antibodies, and small molecules to target a wide range of malignancies within the biological cancer therapy market. It has an oncology pipeline that includes mRNA cancer vaccines, bispecific antibodies, antibody-drug conjugates, and CAR-T programs supported by RNA-based CARVac technology.
Financial Highlights (FY 2024)
Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***
This information is available for BCC Research members only.
BIONTECH SE In News
Company's Business Segments
- Product : mRNA Vaccines, Oncology, Infectious diseases Vaccines, Others
- Service : Research and Development, Vaccine Production, Others
Applications/End User Industries
- Healthcare
- Oncology
- Pharmaceuticals
- Manufacturing